Founding and managing partner Marc E. Kasowitz was a featured speaker on the panel “Examining The Activist Model” at the Managed Funds Association Outlook 2016 Conference on October 20, 2016.
Kasowitz Client Mozido Wins Dismissal of Claims by Philip Geier, Jr., Former Chairman and CEO of Interpublic
The Delaware Chancery Court granted Kasowitz client Mozido, LLC, a global provider of trusted digital commerce and payment solutions, dismissal of all claims brought by Philip Geier.
David S. Rosner and Michael Hanin Discuss Hedge Fund Litigation at Corporate Counsel Summit
Kasowitz partners David S. Rosner and Michael Hanin moderated the panel “Recent Trends in Hedge Fund Litigation” at Corporate Counsel’s 10th Annual Hedge Fund General Counsel and Compliance Officer Summit ...
Daniel J. Fetterman Co-Chairs 4th Annual “Defending Corporations and Individuals in Government Investigations” Conference in Washington, DC
Kasowitz partner Daniel J. Fetterman co-chaired the 4th Annual “Defending Corporations and Individuals in Government Investigations”
The National Law Journal Names Sheron Korpus Antitrust and Mergers & Acquisitions Trailblazer
The National Law Journal has named partner Sheron Korpus an “Antitrust and Mergers & Acquisitions Trailblazer.”
Kelly A. Frawley Discusses Potential Custodial Issue in High-Profile Celebrity Divorce
Responding to the news that Angelina Jolie has filed for divorce from Brad Pitt, Kasowitz partner Kelly A. Frawley has been quoted by numerous news outlets regarding the custodial issues often present in high-profile divorces.
Conversation and Cocktails with Senator Lieberman
Mr. Kasowitz, known as the “toughest lawyer on Wall Street,” and Senator Lieberman, who was a leader in shaping legislation in virtually every major area of public policy, discussed a variety of topics including the Presidential election and the state of global affairs.
Sheron Korpus Comments on Second Circuit Vitamin C Antitrust Comity Ruling
The Second Circuit vacated a $147 million district court judgment against Chinese companies Hebei Welcome Pharmaceutical Co. Ltd. and North China Pharmaceutical Group Corp. for violating U.S. antitrust law by participating in an illegal cartel to fix the price and limit the supply of vitamin C for export.